124 related articles for article (PubMed ID: 38490045)
1. Platinum (IV) drugs with cannabidiol inducing mitochondrial dysfunction and synergistically enhancing anti-tumor effects.
Wei T; Chen L; Shi P; Wang C; Peng Y; Yang J; Liao X; Yang B; Gao C
J Inorg Biochem; 2024 May; 254():112515. PubMed ID: 38490045
[TBL] [Abstract][Full Text] [Related]
2. Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis.
Liu Z; Cai J; Jiang G; Wang M; Wu C; Su K; Hu W; Huang Y; Yu C; Huang X; Cao G; Wang H
Eur J Med Chem; 2024 Jan; 263():115968. PubMed ID: 37995563
[TBL] [Abstract][Full Text] [Related]
3. Novel 4-Amino-Quinazoline moieties ligated Platinum(IV) prodrugs overcome cisplatin resistance in EGFR
Li R; Zhao W; Jin C; Xiong H
Bioorg Chem; 2023 Jun; 135():106499. PubMed ID: 37058978
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
Wang M; Li G; Jiang G; Cai J; Zhong W; Huang R; Liu Z; Huang X; Wang H
Eur J Med Chem; 2024 Feb; 266():116095. PubMed ID: 38215589
[TBL] [Abstract][Full Text] [Related]
5. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism.
Wu Y; Zhao D; Shang J; Huang W; Chen Z
Dalton Trans; 2022 Jul; 51(29):10930-10942. PubMed ID: 35731536
[TBL] [Abstract][Full Text] [Related]
6. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.
Göschl S; Schreiber-Brynzak E; Pichler V; Cseh K; Heffeter P; Jungwirth U; Jakupec MA; Berger W; Keppler BK
Metallomics; 2017 Mar; 9(3):309-322. PubMed ID: 28205649
[TBL] [Abstract][Full Text] [Related]
9. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
10. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
11. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
[TBL] [Abstract][Full Text] [Related]
12. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
13. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
[TBL] [Abstract][Full Text] [Related]
14. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs.
Liu X; Wenisch D; Dahlke P; Jordan PM; Jakupec MA; Kowol CR; Liebing P; Werz O; Keppler BK; Weigand W
Eur J Med Chem; 2023 Sep; 257():115515. PubMed ID: 37295160
[TBL] [Abstract][Full Text] [Related]
15. Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction.
Liu Z; Wang M; Huang R; Hu T; Jing Y; Huang X; Hu W; Cao G; Wang H
J Med Chem; 2023 Apr; 66(7):4868-4887. PubMed ID: 36946996
[TBL] [Abstract][Full Text] [Related]
16. Necrosis-Inducing High-Valent Oxo-Rhenium(V) Complexes with Potent Antitumor Activity: Synthesis, Aquation Chemistry, Cisplatin Cross-Resistance Profile, and Mechanism of Action.
Das S; Joshi P; Patra M
Inorg Chem; 2023 Dec; 62(48):19720-19733. PubMed ID: 37974075
[TBL] [Abstract][Full Text] [Related]
17. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
18. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Barth MC; Häfner N; Runnebaum IB; Weigand W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982792
[TBL] [Abstract][Full Text] [Related]
20. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
